P 13
Alternative Names: P-13; Peptide P-13Latest Information Update: 14 Sep 2023
Price :
$50 *
At a glance
- Originator Unknown
- Developer 13therapeutics
- Class Anti-inflammatories; Peptides
- Mechanism of Action Myeloid differentiation factor 88 inhibitors; Toll-like receptor 2 antagonists; Toll-like receptor 4 antagonists; Toll-like receptor 9 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Noise-induced hearing loss; Otitis media
Most Recent Events
- 07 Sep 2023 P 13 is still in preclinical development for Noise-induced hearing loss and Otitis media in USA (13therapeutics website, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Noise-induced hearing loss in USA
- 28 Aug 2020 No recent reports of development identified for preclinical development in Otitis-media in USA